Skip to main navigation Skip to search Skip to main content

Purpura Schonlein - Henoch erfolgreiche therapie mit dapson

Translated title of the contribution: Henoch-Schonlein purpura: Successful treatment with dapsone
  • Jörg Albrecht
  • , Martin Mempel
  • , Rüdiger Hein
  • , Dietrich Abeck
  • , Johannes Ring

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

A 26-year old patient who suffered from purpura for four years evolved into the complete clinical picture of Henoch-Schonlein-purpura in the past two years. A causative agent was never found. Multiple therapeutic approaches including systemic steroids, azathioprine as well as pentoxyfylline failed to control the arthralgias, intestinal symptoms and skin lesions. Therefore dapsone therapy was initiated at a dosage of 100 mg daily after checking the glucose-6-phosphate-dehydrogenase and with regular control of the blood methemoglobin level. Within two weeks, the patient's symptoms completely cleared, he has now been in remission for the past six months. As noted elsewhere, dapsone is an effective therapy for severe cases of Henoch- Schonlein-purpura.

Translated title of the contributionHenoch-Schonlein purpura: Successful treatment with dapsone
Original languageGerman
Pages (from-to)809-811
Number of pages3
JournalHautarzt
Volume50
Issue number11
DOIs
StatePublished - Nov 1999

Fingerprint

Dive into the research topics of 'Henoch-Schonlein purpura: Successful treatment with dapsone'. Together they form a unique fingerprint.

Cite this